Cargando…

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

PURPOSE: MET is a notable driver gene in the diversity of aberrations with clinical relevance, including exon 14 skipping, copy number gain, point mutations, and gene fusions. Compared with the former two, MET fusions are severely under‐reported, leaving a series of unanswered questions. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Hui, Zhang, Junhua, Chen, Tong, Wang, Mingzhao, Chen, Dongna, Si, Tongguo, Liu, Yutao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358190/ https://www.ncbi.nlm.nih.gov/pubmed/37326363 http://dx.doi.org/10.1002/cam4.6047

Ejemplares similares

Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study
por: Sun, Fangfang, et al.
Publicado: (2023)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
por: Chen, Bowen, et al.
Publicado: (2022)

Real-world insights into patients with advanced NSCLC and MET alterations
por: Bittoni, Marisa, et al.
Publicado: (2021)

Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting
por: Ai, Xinghao, et al.
Publicado: (2022)

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
por: Chen, Dongna, et al.
Publicado: (2023)

Tackling CASMI 2012: Solutions from MetFrag and MetFusion
por: Ruttkies, Christoph, et al.
Publicado: (2013)

Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study
por: Shen, Lesang, et al.
Publicado: (2022)

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China
por: Peng, Wanren, et al.
Publicado: (2020)

PB2399: BRENTUXIMAB VEDOTIN IN TREATING CHINESE PATIENTS WITH LYMPHOMA:A MULTICENTER,REAL-WORLD STUDY
por: Zhang, Xudong, et al.
Publicado: (2023)

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group
por: Zheng, Yu-Xin, et al.
Publicado: (2022)

The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real‐world multicenter study
por: Fei, Xiaochen, et al.
Publicado: (2021)

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
por: Yang, Weili, et al.
Publicado: (2023)

Adherence to omalizumab: A multicenter "real-world" study
por: Campisi, Raffaele, et al.
Publicado: (2020)

Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China
por: Wang, Shuo, et al.
Publicado: (2021)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Comprehensive analysis of prognostic value of lymph node classifications in esophageal squamous cell carcinoma: a large real-world multicenter study
por: Wen, Junmiao, et al.
Publicado: (2021)

Lymph node metastasis in Chinese patients with clinical T1 non‐small cell lung cancer: A multicenter real‐world observational study
por: Chen, Bing, et al.
Publicado: (2019)

Safety of Shujinjianyao pill in clinical real world: A prospective, observational, multicenter, large-sample study Protocol
por: Cui, Xin, et al.
Publicado: (2019)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Cao, Fei, et al.
Publicado: (2021)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met
por: Tong, Mengya, et al.
Publicado: (2019)

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study
por: Zhou, Shengyu, et al.
Publicado: (2023)

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

Real-World Experience of NTRK Fusion–Positive Thyroid Cancer
por: Park, Jong Chul, et al.
Publicado: (2022)

A glioneuronal tumor with CLIP2-MET fusion
por: Chowdhury, Tamrin, et al.
Publicado: (2020)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

MODL-06. Targeting c-MET in combination with radiation is effective in MET-fusion driven high-grade glioma
por: Zuckermann, Marc, et al.
Publicado: (2022)

Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis
por: Yang, Ping, et al.
Publicado: (2023)

Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
por: Zhang, Xinhua, et al.
Publicado: (2023)

Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns
por: Lee, Jessica K., et al.
Publicado: (2021)

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
por: Westphalen, C. B., et al.
Publicado: (2021)

Real-world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: a multicenter study
por: Tang, Tengqian, et al.
Publicado: (2021)

Real-world data on severe lung cancer: a multicenter retrospective study
por: Wang, Fei, et al.
Publicado: (2023)

Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study
por: Yang, Xiawan, et al.
Publicado: (2020)

Polyethylene glycol recombinant human growth hormone in Chinese prepubertal slow-growing short children: doses reported in a multicenter real-world study
por: Chen, Jiajia, et al.
Publicado: (2022)

Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study
por: Wang, Yu-tong, et al.
Publicado: (2023)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
por: Wang, Mingzhao, et al.
Publicado: (2023)

Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
por: Morrisette, Taylor, et al.
Publicado: (2021)

Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
por: Sakkat, Abdullah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jk3kd8eakpcshjsu3bgisdrrvi